Pomalidomide, bortezomib, and dexamethasone in lenalidomide-pretreated multiple myeloma: A subanalysis of OPTIMISMM by frailty

• Published in: Journal of clinical oncology Vol. 40; no. 16_suppl; p. 8024
• Main Authors: Oriol Rocafiguera, Albert, Dimopoulos, Meletios A., Schjesvold, Fredrik, Beksac, Meral, Yagci, Münci, Larocca, Alessandra, Guo, Shien, Mu, Yutian, Hong, Kevin, Dhanasiri, Sujith, Richardson, Paul G., Weisel, Katja
• Format: Journal Article
• Language: English
• Published: 01.06.2022

8024 Background: Patients (pts) with multiple myeloma (MM) are likely to be older adults, and advanced age is associated with lower survival rates, in part due to comorbidities and frailty. Results from the phase 3 OPTIMISMM trial (NCT01734928) demonstrated that pomalidomide (P) in combination with...